Stay updated with breaking news from Ericaf Sim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First and only U.S. approval of a maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease and severe LRTD due to RSV FDA’s decision is...
Late-stage trials show Pfizer RSV vaccine candidate to be more than 80 percent effective at preventing severe illness in babies and seniors.
Pfizer announced that its respiratory syncytial virus (RSV) vaccine showed an efficacy of 82 percent against hospitalization in infants under 90 days old, and 69 percent among those younger than six months.
In a Phase III trial, Pfizer's RSVpreF, a bivalent RSV vaccine, protected infants against severe medically attended lower respiratory tract illness when administered during the second or third trimester.